Currently, CSF and positron emission tomography (PET) biomarkers, including Aβ, tau, and neurofilament light chain (NfL), are employed for the prediction of dementia onset and progression from mild cognitive impairment (MCI) to AD [187,188]. This evidence concerns the gene MAPT and dementia.